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Abstract
Background: Isolated hypothalamic-pituitary Langerhans cell histiocytosis (HPLCH) is very rare. We investigated the
clinicopathological characteristics, endocrine function changes, BRAFV600E mutations and treatments of isolated
HPLCH.
Methods: We identified seven patients with isolated HPLCH by reviewing the clinical and pathological files in our
hospital from 2007 to 2015. The clinical characteristics of the seven patients were retrospectively reviewed,
especially the endocrine function changes. Immunostaining and mutation profiling of BRAFV600E were performed.
Results: The seven HPLCH patients included three men and four women, aged 9–47 years. All patients presented
with symptoms of central diabetes insipidus (CDI), and four displayed anterior pituitary hypofunction as well.
Magnetic resonance imaging showed hypothalamic-pituitary axis involvement in all patients. There was no
evidence for the involvement of other organs in all seven patients. Langerhans cell histiocytosis was confirmed by
neuroendoscopic procedures, and immunohistochemical staining showed that all cases (7/7) were positive for
CD68, CD1a, Langerin, and S-100. The BRAFV600E mutation was detected in three of the six cases (3/6). Six patients
had follow-up information; all received desmopressin acetate and high-dose corticosteroid therapy, and two
patients received radiotherapy.
Conclusions: Our study indicated that all patients with isolated HPLCH had CDI as the earliest symptom, and more
than half of the patients had anterior pituitary deficiencies. The BRAFV600E mutation is a common genetic change in
HPLCH patients. Treatment of HPLCH patients is difficult, and the progressive loss of endocrine function is
irreversible in most cases.
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Background
Langerhans cell histiocytosis (LCH) is characterized by
the idiopathic proliferation of specialized bone marrow-
derived Langerhans cells and mature eosinophils. LCH
can affect any organ or system and may be systemic or
localized [1, 2]. Patients with isolated hypothalamic-
pituitary (HP) LCH are very rare, although patients with
multisystemic LCH often show pituitary gland invol-
vement [3–7]. Among the endocrine regions, LCH is
frequently found in the HP region, resulting in diabetes
insipidus (DI), the most common endocrine anomaly
[8–12]. Anterior pituitary involvement also occurs as a
result of the disease process. However, anterior pituitary
dysfunction is not invariably associated with abnormal
HP region imaging, and it is almost always encountered
in patients with multisystemic disease who show DI
and HP pathology on magnetic resonance imaging
(MRI) [6, 8]. The anterior pituitary endocrine function
changes in isolated LCH limited to the HP region have
been poorly studied.
Recently, LCH patients were shown to have a high
frequency of BRAFV600E mutations and to respond to
RAF inhibitors, suggesting that LCH is more likely a
neoplastic than a reactive disorder. The BRAFV600E
mutations are present in approximately 25–60 % of LCH
cases [13–20], but this mutation has not been reported
in isolated HPLCH in previous publications.
Several studies on LCH patients, which examined rela-
tively small numbers of patients, have provided informa-
tion on the evolution of pituitary dysfunction as well as
the morphological changes in the HP region [3–7].
However, no large studies have examined patients with
isolated HPLCH and assessed the pituitary function
without interference from other organs. In the current
study, we retrospectively studied seven patients with
isolated HPLCH in our hospital from 2007 to 2015 and
analysed their clinical and pathological features, endo-




We reviewed all surgical biopsy or resection records in
the Peking Union Medical College Hospital from January
1, 2007 to December 31, 2015 and identified a total of
seven cases with isolated HPLCH. The patients’ medical
records, including patient complaints, brain MRI find-
ings, evaluation of anterior pituitary function, evaluation
of other organs, and treatment, were collected and
reviewed. No patient had a history of LCH. The HP
regions of the patients were evaluated by MRI scans
before and after treatment. The pre-treatment basal
levels of growth hormone (GH), insulin-like growth
factor-1 (IGF1), adrenocorticotropic hormone (ACTH),
cortisol, free thyroxine (FT4), thyroid-stimulating
hormone (TSH), prolactin (PRL), luteinizing hormone
(LH), follicle-stimulating hormone (FSH), oestradiol, and
testosterone were measured early in the morning in
conjunction with plasma and urine osmolality tests. A
water deprivation test was performed to assess vaso-
pressin deficiency. In four patients with suspected pituit-
ary dysfunction, dynamic pituitary function tests were
employed, including the insulin tolerance test for assess-
ments of GH and/or ACTH/cortisol reserves, thyrotropin-
releasing hormone and gonadotropin-releasing hormone
stimulation tests, and insulin-induced hypoglycaemia test.
The pituitary functions of the patients were evaluated
endocrinologically at least once per year. Methods used to
evaluate other organs included a B ultrasound, computed
tomography (CT), full-body bone scans, and a bone
marrow biopsy. In addition, two patients received positron-
emission tomography/computerized tomography (PET/
CT). All patients received endoscopic transnasal transsphe-
noidal biopsy or resection of the HP regions. All samples
were fixed in 10 % neutral buffered formalin, routinely
processed, and embedded in paraffin. Haematoxylin-eosin-
stained sections were observed using optical microscopy
and reviewed independently by three experienced patholo-
gists. The pathological diagnosis of LCH was based on the
World Health Organization (WHO) criteria for LCH [1, 2].
We collected follow-up data from outpatient follow-ups.
Immunostaining
Immunostaining of CD1a (EP3622, 1:200; ZSJQ-BIO,
Beijing, China), S-100 (polyclonal, prediluted; ZSJQ-
BIO, Beijing, China), Langerin (12D6, prediluted;
ZSJQ-BIO, Beijing, China), and CD68 (KP-1, 1:100;
Dako, Glostrup, Denmark) was performed for all
seven cases according to the manufacturer’s instruc-
tions. Immunostaining was performed on 4 μm-thick
unstained sections cut from representative formalin-
fixed paraffin-embedded (FFPE) blocks. For all markers,
positive controls and negative controls were used. For
CD68, signals appearing as tan particles in the cytoplasm
were considered positive. For S-100, tan particles in the
nucleus or cytoplasm were considered positive. For CD1a,
tan particles in the membrane were considered positive.
For Langerin, tan particles in the membrane or cytoplasm
were considered positive.
Detection of BRAFV600E mutations
Genomic DNA from six cases of HPLCH (the tissue of
the last case was not sufficient for further study) was
extracted from freshly cut FFPE tissue sections using a
QIAamp DNA Mini Kit (Qiagen, Germany) according to
the manufacturer’s instructions. The area of the highest
histiocyte density was identified through haematoxylin-
eosin staining, and tissue from this area in unstained
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sections was scraped for DNA extraction. The extracted
DNA was then quantified using a Qubit dsDNA BR
assay (Life Technologies, USA). DNA from all six cases
of LCH was successfully amplified. Analysis of
BRAFV600E mutations was performed with a BRAF
V600E Mutation Detection Kit (Amoy Diagnostics Co.,
Ltd., China) according to the manufacturer’s instruc-
tions. Real-time quantitative polymerase chain reaction
(QPCR) was carried out on an Applied Biosystems7500
QPCR Platform (Life Technologies, USA). The cycling
conditions for quality control (QC) runs and for muta-
tion assays were as follows: 5 min incubation at 95 °C,
followed by 15 cycles of 95 °C for 25 s, 64 °C for 20 s,
and 72 °C for 20 s, and finally 31 cycles of 95 °C for
25 s, 60 °C for 35 s, and 72 °C for 20 s. Fluorescence was
measured at 60 °C. Mutation data were interpreted
according to the kit manual after curve analysis and
calculation of ΔCt values.
Results
Clinical data
The seven cases of isolated HPLCH (Table 1) included
three men and four women, aged 9–47 years. All seven
patients had symptoms before the diagnosis, and the
major complaint was polyuria and polydipsia (7/7). In
addition, one female patient had secondary amenorrhoea
(1/7), and one child patient showed growth retardation
(1/7). No patients had visual field defects. All patients
had no history of the smoking and drinking. The interval
between onset of symptoms and diagnosis was 1–
108 months. Before the LCH diagnosis by pathology, all
seven patients had been diagnosed with central diabetes
insipidus (CDI), and a mass was found in the HP region
by MRI. Chest CT scans, abdominal B ultrasound, and
full-body bone scans were performed in all seven cases,
but no positive findings were obtained. Two patients
received PET/CT scans, and there were no positive
findings except in the HP region.
MRI showed pituitary stalk thickening in all seven
patients, which was moderate (3.0–7 mm) in three
patients including one child, and marked (>7 mm) in
four patients including two children. In two cases, the
lesion extended to the hypothalamus, and in the other
two cases, the anterior pituitary was clearly involved.
Optic chiasma involvement was not observed. All
patients received gadolinium-enhanced MRI scans, and
all showed enhancement (Fig. 1a, b). There were no
hyperintense signals on T1WI in the posterior pituitary
lobe in all seven patients. PET/CT was carried in two
patients, and high uptake was observed in the pituitary
stalk. The detailed results of the patients’ MRI scans of
the HP region are listed in Table 2.
Anterior pituitary function
Four patients had anterior pituitary deficiency. Three of
the four patients showed whole anterior pituitary defi-
ciency, and the other patient had GH deficiency (GHD)
and hypogonadism before diagnosis but developed whole
anterior pituitary deficiency in the following 4 months.
Three patients had normal anterior pituitary function
before diagnosis, and anterior pituitary function was also
normal in two patients in the following 2 and 5 months,
respectively. Data on the anterior pituitary function of
the third patient was absent (details in Table 3).
Pathological and immunohistochemical findings
Surgery of the HP region was performed in all cases
and was conclusive in all cases. Six patients received
a biopsy, and one patient received a complete mass
resection. Macroscopically, the maximum diameter of
the samples ranged from 3 to 10 mm, and all tissues
were yellow or white. Microscopically, all lesions con-
sisted of accumulated mononuclear histiocytic cells.
The lesions in all seven cases were predominantly
composed of histiocytic cells and a variable fraction
of eosinophils (Fig. 2a). The nuclei of the histiocytic
cells were characteristic slightly eccentric, ovoid, or
reniform, with linear grooves and inconspicuous nu-
cleoli. The cytoplasm was abundant and pale to
eosinophilic. Mitotic figures were seldom observed,
Table 1 Clinical profile and follow-up data of seven patients with hypothalamic-pituitary Langerhans cell histiocytosis
No. Age (years)/ Gender The interval between onset of
symptoms and diagnosis
CDI Sites of involvement Follow-up Therapy
(months) At presentation Follow-up
1 9 / Female 108 Present PS None Alive, 39 ms RT + HRT
2 47 / Female 1 Present PS PS Alive, 5 ms HRT
3 12 / Female 36 Present PS + H PS + H Alive, 5 ms HRT
4 22 / Male 2 Present PS + P NA NA NA
5 13 / Male 4 Present PS + H None Alive, 41 ms RT + HRT
6 15 / Male 1 Present PS + P PS + P Alive, 2 ms HRT
7 35 / Female 18 Present PS Liver involvement suspected Died, 74 ms RT + Surgery + HRT
PS pituitary stalk, H hypothalamus, P pituitary, NA not available, RT radiotherapy, CDI central diabetes insipidus, HRT hormone replacement therapy
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and no necrosis was found in all cases. Eosinophils
infiltration was easily observed. Touton giant cells
were absent in all cases. Immunohistochemical stain-
ing for CD1a (Fig. 2b), Langerin (Fig. 2c), S-100
(Fig. 2d), and CD68 was positive in the histiocytic
cells of all 7 LCH cases (7/7).
BRAF V600E gene status
BRAF V600E mutations were found in three cases (3/6)
of HPLCH using QPCR in 6 successfully amplified cases
(Fig. 3a, b).
Treatment and outcomes
Six cases had follow-up data (range 2–74 months, details
in Table 3). All patients received desmopressin acetate
and high-dose corticosteroid therapy. In four patients
with anterior pituitary deficiency, three were also treated
with Letrox, and one patient received testosterone
replacement therapy. Two patients with whole anterior
pituitary deficiency received focal radiotherapy of the
HP regions (total dose: 30.5 Gy). One patient underwent
surgical resection after CyberKnife radiosurgery (de-
tails not available) in another hospital. No patients
received chemotherapy. During the follow-up, no pa-
tients developed extrapituitary involvement, except
one patient who died and had suspected liver involve-
ment, but no direct proof, 74 months after resection.
Among the five remaining patients, three patients
survived with diseases, and two patients who received
RT survived without diseases. One patient was lost to
follow-up after biopsy.
Discussion
Langerhans cell histiocytosis (LCH) is a rare heteroge-
neous histiocytic disorder, and the dominant sites of
involvement are bone and adjacent soft tissue, liver,
spleen and bone marrow [1, 2, 15]. The central nervous
system (CNS) may also be involved [2, 21]. In patients
Fig. 1 a. MRI scan of the lesion (arrow) in a 9-year-old child (case 1) before diagnosis demonstrated that the upper pituitary stalk was thickened,
and a well-circumscribed and regular homogeneous enhanced mass was observed (sagittal T1 contrast-enhanced images). b. MRI scan of the
lesion in case 1 at 11 months of follow-up demonstrated that the pituitary stalk (arrow) was fine and the homogeneous enhanced mass had
regressed, but the anterior pituitary narrowed (sagittal T1 contrast-enhanced images)












1 Absent Normal 7.1 Absent Single Isointensity Isointensity Homogeneous Relatively clear Regression
2 Absent Normal 7.0 Absent Single Isointensity Isointensity Homogeneous Relatively clear Stable
3 Absent Normal 6.6 Present Single Isointensity Isointensity Homogeneous Irregular Increased, PS
enlargement
4 Absent Enlarged 5 Absent Single Isointensity Isointensity Homogeneous Obscure Not available
5 Absent Normal 8.5 Present Single Isointensity Isointensity Homogeneous Relatively clear Regression





7 Absent Normal 9 Absent Single Isointensity Isointensity Homogeneous Relatively clear Regression
AP anterior pituitary, WPS width of the pituitary stalk, HI hypothalamus involvement, PI pituitary involvement
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Table 3 Anterior pituitary function at presentation and during follow-up
No. At presentation Follow-up























1 Panhypopituitary 0.2 25 15.29 0.81 0 0.2 15.84 10.4 11.2 0.202 0.56 Panhypopituitary
2 Not impaired 0.5 129 28. 6 13.51 3.12 4.91 37.1 44 0.19 1.54 1.22 Not impaired
3 GH, LH-FSH deficiency <0.05 72 26.3 12.05 0.43 0.36 17.39 25 <0.1 8.485 1.01 Panhypopituitary
4 Not impaired 1.4 198 30.6 12.9 2.63 1.0 15.6 11.8 360.8 2.662 1.380 NA
5 Panhypopituitary <0.05 44 7.6 0.74 0 0.3 11.7 10.2 5.2 2.539 0.60 Panhypopituitary
6 Not impaired 0.2 381 51.3 13.65 4.7 4.42 18.14 56 2.11 2.581 1.333 Not impaired
7 Panhypopituitary 0.12 68 7.6 0.2 5.2 1.67 51.22 0.09 0.73 0.26 0.77 Panhypopituitary
AP anterior pituitary, GH growth hormone, IGF1 insulin-like growth factor-1, ACTH adrenocorticotropic hormone, LH luteinizing hormone, FSH follicle-stimulating hormone, PRL prolactin, E2 oestradiol, T testosterone,












with LCH in the HP region, most cases are extended
from osseous foci in multifocal or disseminated LCH,
but unifocal or multifocal infiltrates can occur primarily
within or even restricted to the HP region and other
sites, such as the infundibulum, optic chiasm, and
choroid plexus [2–7, 22, 23]. However, isolated HPLCH
without the involvement of other organs is a rare condi-
tion, and there are few reports on the various character-
istics of this disease state, including the evaluation of
pituitary function, especially anterior pituitary function, the
BRAFV600E mutation status, and other clinicopathological
features. Here, we reviewed seven cases of isolated LCH
limited to the HP region and investigated the clinico-
pathological characteristics, endocrine function changes,
BRAFV600E mutations and treatment of the lesions.
The aetiology of the histiocytic lesions is largely
unknown [1, 2]. Although the underlying aetiology of
the condition has long been enigmatic, recent studies
Fig. 3 a. The point mutation V600E of BRAF was identified in case 2 by the QPCR method. b. No BRAF mutation was found in case 5 by
the QPCR method
Fig. 2 a. The lesion was predominantly composed of histiocytic cells and eosinophils (haematoxylin and eosin stain, 200×). b. The histiocytic
cells were immunopositive for CD1a (400×). c. The histiocytic cells were immunopositive for Langerin (400×). d. The histiocytic cells were
immunopositive for S-100 (400×)
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have suggested that LCH is due to clonal neoplastic
proliferation of myeloid-derived precursor cells, with a
high frequency of somatic oncogenic BRAFV600E muta-
tions in 25–60 % of LCH patients [13–20]. In CNS,
BRAF alterations are found in variable frequencies
across a wide spectrum of diverse neoplasms, such as
various glial and glioneuronal tumours, craniopharyngio-
mas, LCH and brain metastases [16]. No association
between the BRAFV600E mutation and survival has been
found in LCH, but several case reports described an
impressive response to a BRAF inhibitor in patients with
BRAF V600E-mutated LCH [19]. As an independent
condition, the data on the BRAF V600E mutation in
isolated HPLCH is unclear, and one reason for this may
be the low number of cases. In this report, we examined
seven cases of isolated HPLCH, and we had sufficient
quantities of tissue for mutation detection in six cases.
The results of our study showed that BRAFV600E was
mutated in 50 % of patients with HPLCH, suggesting
that the mutation rate in isolated HPLCH is consistent
with the reported rates in LCH involving other sites.
Because the follow-up time for some patients was short
in our study, the relationship of BRAFV600E mutation
and survival was not analysed. Smoking is an important
factor in primary LCH of the lung [17], but all seven
patients had no history of smoking in our study, suggest-
ing that smoking is not related to HPLCH.
Clinically, LCH can occur at any age but typically
occurs in the paediatric population [1, 6, 10]. The most
common neurological signs of LCH are CDI with or
without associated signs of hypothalamic dysfunction,
increased intracranial pressure, cranial nerve palsies, and
seizures [2]. Isolated CDI may be an early diagnostic
signature in patients with an abnormal lesion in the HP
region and no past medical history, and the association
of polyuria-polydipsia suggests that a complete endo-
crine evaluation and a meticulous MRI examination of
the HP region should be performed [2, 4, 6–10]. Patients
with unifocal disease are usually older children or adults
[1]. In our cohort, four patients were children aged 9–15
years, and three patients were adults. Our study had
slightly more children with isolated HPLCH than adults.
There was no specific gender preference in our study,
which had slightly more females than males. The most
common sign was CDI (polyuria and polydipsia, 100 %),
and other symptoms included secondary amenorrhoea
(1/7) and growth retardation (1/7).
While CDI is the most common HP symptom, an-
terior pituitary deficiencies are less common. Several
studies have shown that most patients with HP lesions
had one or more anterior pituitary deficiencies, and
hormone deficiencies may be present at diagnosis or
appear gradually during the course of disease [2–8, 11].
Regular monitoring of these patients is recommended.
Growth hormone deficiency is the most frequent
disease-related anterior pituitary deficiency and is found
in up to 50 % of patients, followed by gonadotrophin
deficiency, but ACTH and TSH are relatively less com-
mon; moderately elevated PRL levels are infrequently
found and are attributed to pituitary stalk involvement
[8]. Established deficiencies almost never recover over
time. In our cohort, more than a half of the patients with
HPLCH had anterior pituitary deficiencies at diagnosis
with a mean interval from the first symptoms to diagno-
sis of 42 months. Three patients were diagnosed with
normal anterior pituitary functions, and the intervals
from the first symptoms to diagnosis were less than
2 months for all of them. Our study suggested that the
interval from the first symptoms to diagnosis may be
related to the anterior pituitary function, and the le-
sions progressed with time. All patients had posterior
pituitary deficiencies at diagnosis, and polyuria and
polydipsia were the first symptom in all patients;
thus, a MRI scan is necessary for patients presenting
with polyuria and polydipsia.
MRI changes in patients with LCH of CNS include the
following: 1) intracranial, extra-axial changes of the
hypothalamic-pituitary region (50 %), meninges (29 %)
or choroid plexus (6 %); 2) intracranial, intra-axial
changes of white matter and gray matter (36 %); and 3)
cerebral atrophy (8 %) [2]. There are several studies on
the MRI changes in HPLCH, and pituitary stalk thicken-
ing can be observed in LCH in the HP regions [4, 6]. In
our cohort, the MRI features of patients with HPLCH
included the following characteristics: 1) a single lesion
on the HP region and involvement of the pituitary
stalk; 2) isointensity signals on both T1WI and T2WI
in most cases; 3) homogeneous enhancement in most
cases; 4) relatively clear borders in most cases. Al-
though these are characteristic MRI findings, it is
difficult to distinguish HPLCH from other diseases,
such as germinoma or lymphocytic thyroiditis.
An accurate pathological diagnosis of LCH is neces-
sary for further treatment and follow-up depending on
the classic pathomorphological and immunohistochemi-
cal features. Recently, the use of neuroendoscopic biopsy
for suprasellar masses has increased, and with this
technique, it is possible to obtain an accurate patho-
logical diagnosis [24], although sometimes the patho-
logical diagnosis is difficult due to small specimens with
prominent sampling artefacts and haemorrhage [25].
Distinguishing this condition from other diseases that
can cause CDI, such as craniopharyngioma, germinoma,
sarcoidosis, hypophysitis, and tuberculosis, is essential
[2, 10, 26], and the pathological signature with both
CD1a-positive, Langerin-positive, and S-100-positive in-
filtrating histiocytes and increased presentation of eosin-
ophils has made the differential diagnosis relatively easy.
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In addition, differentiation from other non-Langerhans
cell histiocytoses, such as Erdheim-Chester disease or
Rosai-Dorfman disease, is also important. Although S-
100 positive cells can be found in Erdheim-Chester
disease (ECD) and Rosai-Dorfman disease, CD1a is
always negative in the same histiocytes [1, 2]. Notably,
the BRAFV600E mutation was detected in more than
60 % of patients with ECD [27], but this mutation could
not distinguish ECD from LCH because it was detected
in approximately 25–60 % of the latter samples [13–20].
In our cohort, the seven isolated HPLCH cases that we
assessed had been confirmed by pathomorphological
changes and immunohistochemical findings during neu-
roendoscopic transnasal transsphenoidal surgery, includ-
ing six cases by biopsy and one by resection, and all
cases were simultaneously positive for CD1a, Langerin
and S-100. In addition, we evaluated the status of other
organs in all patients, which is required to exclude the
multisystemic lesions, and there was no evidence of
other system involvement in all patients.
The overall 5-year survival rate of LCH patients is
88 %. Patients with unifocal LCH have an excellent
prognosis and a high long-term survival rate (99 %) and
may spontaneously recover or require minimal treat-
ment [1, 28]. In our cohort, one patient died of liver
disease, but we had no evidence of liver involvement
with LCH; the other six patients were still alive, and
further follow-up should be performed. No lesions were
spontaneously recovered in our study. The treatments
for LCH involving the CNS, such as conservative treat-
ment, surgical intervention, chemotherapy and radio-
therapy, were dependent on the lesion location, size,
number and symptoms, and high-dose corticosteroid
therapy was also used to control the inflammatory
process. Additionally, CyberKnife radiosurgery was per-
formed in some patients [2, 21, 28–30]. However, the
treatment of HPLCH patients is controversial because
localized radiotherapy and chemotherapy were associ-
ated with tumour regression and stabilization but did
not appear to prevent the evolution or deterioration of
LCH-associated endocrine deficiency [3–7, 30]. In our
cohort, although remission was observed in the lesions
of two patients after radiotherapy (30.5 Gy) and the
lesion of another patient who received surgical resection
after CyberKnife radiosurgery failure, the patients’ qual-
ity of life was irreversibly impaired because they had
irreversible permanent sequelae, panpituitary hormone
deficiency, and needed to receive goal-directed hormone
replacement therapy and monitor hormone level changes
permanently. The anterior pituitary function of another
patient who received high-dose corticosteroid therapy
only also progressed from GH and LH-FSH deficiency to
panpituitary hormone deficiency. Our study suggested
that the treatment of patients with HPLCH is a difficult
problem, and the deterioration of the endocrine function
appeared to be unrelated to lesion regression; thus, diag-
nosis and treatment as early as possible are essential. In
addition, monitoring the whole body to assess multisyste-
mic involvement is also very important. Moreover, for
patients with BRAFV600E mutations, new targeted therap-
ies, such as vemurafenib, may be used because the results
have been encouraging in select progressive patients with
LCH [17, 31]. Recently, Nakagawa et al. [12] reported two
relapsed females with LCH limited to the pituitary stalk
and found that chemotherapy with cytarabine may be
useful for preventing anterior pituitary hormone defi-
ciency and neurodegenerative disease for new-onset
CDI with LCH, but the further studies are needed to
confirm these results.
Our study has some limitations as it is based on a
small group of selected patients due to the low incidence
of this condition. Notably, the follow-up time is short in
our study because neuroendoscopic biopsy is a new
technique in recent years, and it will be necessary to
follow-up the patients over a longer period of time.
Conclusions
Our study indicated that some cases of isolated LCH
involve only the hypothalamic-pituitary region, and all
patients had CDI as the earliest symptom, with more
than half having anterior pituitary deficiencies. The
BRAFV600E mutation is a common genetic change in
HPLCH patients. The treatment of HPLCH patients is
difficult, and the loss of endocrine function is irrevers-
ible in most cases. For patients with the BRAFV600E
mutation, new targeted therapy may be used when the
lesion is progressing.
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